Search by Drug Name or NDC
NDC 73154-0130-14 XPHOZAH 30 mg 31.9 mg/1 Details
XPHOZAH 30 mg 31.9 mg/1
XPHOZAH 30 mg is a ORAL TABLET, FILM COATED in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Ardelyx, Inc.. The primary component is TENAPANOR.
MedlinePlus Drug Summary
Tenapanor is used to treat irritable bowel syndrome with constipation (IBS-C; a condition that causes stomach pain or cramps, bloating, and infrequent or difficult passage of stools) in adults. Tenapanor is in a class of medications called sodium/hydrogen exchanger (NHE3) inhibitors. It works by increasing the movement of food and waste through the stomach and intestines.
Related Packages: 73154-0130-14Last Updated: 05/26/2024
MedLinePlus Full Drug Details: Tenapanor (Ibsrela)
Tenapanor is used to reduce phosphorus levels in patients with chronic kidney disease (CKD) on dialysis who have not responded to or have not tolerated other therapies. Tenapanor is in a class of medications called sodium/hydrogen exchanger (NHE3) inhibitors. It works by increasing the movement of food and waste through the stomach and intestines, thereby reducing phosphate absorption.
Related Packages: 73154-0130-14Last Updated: 05/26/2024
MedLinePlus Full Drug Details: Tenapanor (Xphozah)
Product Information
| NDC | 73154-0130 |
|---|---|
| Product ID | 73154-130_2443bb1b-63e8-4b35-a9e1-d4a393c2ede5 |
| Associated GPIs | |
| GCN Sequence Number | 085415 |
| GCN Sequence Number Description | tenapanor HCl TABLET 30 MG ORAL |
| HIC3 | C1A |
| HIC3 Description | ELECTROLYTE DEPLETERS |
| GCN | 54892 |
| HICL Sequence Number | 046009 |
| HICL Sequence Number Description | TENAPANOR HCL |
| Brand/Generic | Brand |
| Proprietary Name | XPHOZAH 30 mg |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Tenapanor |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET, FILM COATED |
| Route | ORAL |
| Active Ingredient Strength | 31.9 |
| Active Ingredient Units | mg/1 |
| Substance Name | TENAPANOR |
| Labeler Name | Ardelyx, Inc. |
| Pharmaceutical Class | Organic Anion Transporting Polypeptide 2B1 Inhibitors [MoA], Sodium-Hydrogen Exchanger 3 Inhibitor [EPC], Sodium-Hydrogen Exchanger 3 Inhibitors [MoA] |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA213931 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 73154-0130-14 (73154013014)
| NDC Package Code | 73154-130-14 |
|---|---|
| Billing NDC | 73154013014 |
| Package | 14 TABLET, FILM COATED in 1 BOTTLE (73154-130-14) |
| Marketing Start Date | 2023-10-17 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |